Medical Marijuana, Inc. and AXIM Biotechnologies Form Strategic Alliance to Develop Water-Soluble Cannabinoid Technology

Medical Marijuana, Inc. (OTC: MJNA) announced a strategic alliance with AXIM Biotechnologies, Inc. (OTC: AXIM) to research and develop applications for AXIM's patent covering water-soluble cannabinoids. The alliance centers on AXIM's U.S. Patent No. 11,542,226 B2, titled "Polyfunctional Cannabinoids," which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body. Under the agreement, AXIM assigned to MJNA a 50% right, title, and economic interest in the patent and all associated intellectual property, including rights to existing and future U.S. and foreign patents, licensing and enforcement proceeds, and claims for past infringement.

Concurrently, the companies entered into a Consulting Agreement where AXIM will provide research and development services focused on developing applications for the patent technology. The consulting agreement has an initial non-cancellable term of one year expiring in January 2027, with MJNA paying AXIM a monthly services fee of $62,500. As consideration for the 50% patent interest assignment, MJNA paid $600,000 through the issuance of a secured promissory note to AXIM, accruing interest at 4.75% until maturity on January 15, 2038.

The patented technology represents a significant advancement in cannabinoid delivery. According to the patent details, the engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling dramatically improved absorption and therapeutic delivery. The technology uses patented molecular engineering to link cannabinoids to complementary compounds, substantially improving delivery mechanisms and therapeutic effectiveness. These polyfunctional constructs are engineered to produce more potent responses than individual cannabinoid molecules, potentially allowing for lower therapeutic doses and avoiding toxic side effects associated with higher concentrations.

Dr. Timothy R. Scott, who returned as president of MJNA in conjunction with the alliance, expressed confidence in the partnership. "We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology," stated Dr. Scott. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA." Catalina Valencia, AXIM President, emphasized the technology's potential applications: "We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures."

The technology offers expanded treatment applications for conditions where traditional lipophilic (oil-based) cannabinoids have demonstrated limited bioavailability. This includes potential development of sublingual applications for anxiety and other indications. The alliance combines MJNA's existing knowledge and relationships in the cannabinoid market with AXIM's patented technological advancement, creating what both companies describe as a partnership with significant opportunity for accelerating the development of water-soluble cannabinoid applications.